Low-dose cytarabine (LD-AraC) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for myelodysplastic syndromes (MDS)
Kikuchi
A
A
Ohashi
H
H
Hanada
R
R
Yamamoto
K
K
D000293:Adolescent; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002898:Chromosomes, Human, Pair 8; D003561:Cytarabine / Q000008:administration & dosage; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000235:genetics; D011994:Recombinant Proteins / Q000008:administration & dosage; D016896:Treatment Outcome; D014314:Trisomy
D000964:Antimetabolites, Antineoplastic; D011994:Recombinant Proteins; D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor